NRG CC004

Primary Category:

Cancer Control and Prevention Protocols

Disease Category:

Breast, Gynecologic

Status:

Closed

Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

Eligible for screening study DCP 001

NCT#03180294

NRG CC004 is permanently closed to accrual,  due to drug expiration dates. All patients registered to Step 1 registration by 5pm ET, Friday, April 24, 2020 will be permitted to proceed to the randomization step (Step 2).

This protocol has additional regulatory requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.